Personalized Medicine – Products

Research team in the UK has become the first in Europe to use a 3D spatial multi-omics platform to map tumor architecture and microenvironments at sub-cellular resolution, aiming to uncover new cancer biomarkers for future therapies.

OutSee closed a £2.5M seed round and partnered with o2h discovery to launch a drug discovery program using its AI-powered Nomaly platform, enabling genomics-first target identification and building a pipeline of data-backed therapeutic candidates.

FDA approves Thermo Fisher’s Oncomine Dx Target Test as a CDx to identify NSCLC patients with HER2 mutations eligible for HYRNUO therapy.

Zymo Research partners with biomodal to offer advanced multiomic sequencing, enabling 5mC, 5hmC and genetic analysis from a single DNA sample.

Watchmaker Genomics launches TAPS+, enabling simultaneous detection of methylation and genetic variants for cancer research.

PacBio and Berry Genomics achieve the first regulatory approval in China for clinical long-read sequencing with the Sequel II CNDx system.

Ryvu presents new data on PRMT5 inhibitor RVU305 and ONCO Prime discovery platform for next-generation cancer therapies.

Thermo Fisher Scientific has introduced the Applied Biosystems™ SwiftArrayStudio™ Microarray Analyzer, designed for fast and scalable sample analysis.

Amsbio launches 30+ validated cytokines to improve organoid culture, boosting reproducibility in stem cell and iPSC research.

This whitepaper provides a roadmap for leveraging advanced proteomics platforms to identify biomarkers capable of detecting disease at its earliest stages.